NIR Light‐Triggered Degradable MoTe2 Nanosheets for Combined Photothermal and Chemotherapy of Cancer

Telluride molybdenum (MoTe2) nanosheets with wide near‐infrared (NIR) absorbance are functionalized with polyethylene glycol‐cyclic arginine‐glycine‐aspartic acid tripeptide (PEG‐cRGD). After loading a chemotherapeutic drug (doxorubicin, DOX), MoTe2‐PEG‐cRGD/DOX is used for combined photothermal the...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2018-08, Vol.28 (31), p.n/a
Main Authors: Ma, Ning, Zhang, Ming‐Kang, Wang, Xiao‐Shuang, Zhang, Lu, Feng, Jun, Zhang, Xian‐Zheng
Format: Article
Language:English
Subjects:
Aspartic acid
Biocompatibility
cancer
Chemotherapy
degradable nanosheets
Doxorubicin
Excretion
Glycine
Intermetallic compounds
Materials science
Molybdenum compounds
Nanosheets
Near infrared radiation
Organs
Photodegradation
Photothermal conversion
photothermal therapy
Polyethylene glycol
telluride molybdenum
Tellurides
Toxicity
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Telluride molybdenum (MoTe2) nanosheets with wide near‐infrared (NIR) absorbance are functionalized with polyethylene glycol‐cyclic arginine‐glycine‐aspartic acid tripeptide (PEG‐cRGD). After loading a chemotherapeutic drug (doxorubicin, DOX), MoTe2‐PEG‐cRGD/DOX is used for combined photothermal therapy and chemotherapy. With the high photothermal conversion efficiency, MoTe2‐PEG‐cRGD/DOX exhibits favorable cells killing ability under NIR irradiation. Owing to the cRGD‐mediated specific tumor targeting, MoTe2‐PEG‐cRGD/DOX shows efficient accumulation in tumors to induce a strong tumor ablation effect. MoTe2‐PEG‐cRGD nanosheets, which are relatively stable in the circulation, could be degraded under NIR ray. The in vitro and in vivo experimental results demonstrate that this theranostic nanoagent, which could accumulate in tumors to allow photothermal imaging and combined therapy, is readily degradable in normal organs to enable rapid excretion and avoid long‐term retention/toxicity, holding great potential to treat tumor effectively. A degradable photothermal agent‐mediated, drug‐loaded nanocarrier is developed for photothermal imaging and chemical/photothermal combined therapy. The in vitro and in vivo experimental results demonstrate that this theranostic nanoagent can accumulate in tumors to allow photothermal imaging and combined therapy, and be readily degradable in normal organs to enable rapid excretion and avoid long‐term retention/toxicity.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.201801139